Published in PLoS One on September 30, 2013
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci (2015) 1.02
MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci (2014) 0.97
The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia (2015) 0.86
Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis. J Clin Invest (2015) 0.84
Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells. Biochim Biophys Acta (2014) 0.84
Role of PRMTs in cancer: Could minor isoforms be leaving a mark? World J Biol Chem (2014) 0.80
Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells. Sci Rep (2015) 0.78
Late Cornified Envelope Group I, a novel target of p53, regulates PRMT5 activity. Neoplasia (2014) 0.77
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival. Viruses (2015) 0.75
Multiparameter Evaluation of the Heterogeneity of Circulating Tumor Cells Using Integrated RNA In Situ Hybridization and Immunocytochemical Analysis. Front Oncol (2016) 0.75
The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. Int J Oncol (2017) 0.75
PRMT5 regulates IRES-dependent translation via methylation of hnRNP A1. Nucleic Acids Res (2017) 0.75
Methylosome Protein 50 and PKCδ/p38δ Protein Signaling Control Keratinocyte Proliferation via Opposing Effects on p21Cip1 Gene Expression. J Biol Chem (2015) 0.75
Expression of mep50 in adult and embryos of medaka fish (Oryzias latipes). Fish Physiol Biochem (2016) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res (2005) 29.17
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell (2001) 3.97
Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol (2004) 3.90
microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev (1994) 3.44
Arginine methylation regulates the p53 response. Nat Cell Biol (2008) 2.94
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev (2006) 2.87
mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol (2003) 2.72
The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. J Biol Chem (1999) 2.64
Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev (2010) 2.59
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature (2005) 2.44
Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol Ther (2006) 2.36
A novel WD repeat protein component of the methylosome binds Sm proteins. J Biol Chem (2001) 2.22
Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One (2008) 2.15
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J (2007) 2.08
Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal (2011) 1.90
MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol (2004) 1.89
Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene (2011) 1.83
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell (2010) 1.76
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol (2008) 1.73
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2007) 1.66
Interplay between chromatin remodelers and protein arginine methyltransferases. J Cell Physiol (2007) 1.66
BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol (2004) 1.65
UVB-induced melanocyte proliferation in neonatal mice driven by CCR2-independent recruitment of Ly6c(low)MHCII(hi) macrophages. J Invest Dermatol (2013) 1.57
Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res (1999) 1.46
Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol (2011) 1.40
PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res (2009) 1.33
The histone-binding protein COPR5 is required for nuclear functions of the protein arginine methyltransferase PRMT5. EMBO Rep (2008) 1.33
miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. Int J Biol Sci (2011) 1.33
Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res (2011) 1.30
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer (2010) 1.27
miR-148 regulates Mitf in melanoma cells. PLoS One (2010) 1.21
Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J (2012) 1.15
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. Cancer Sci (2012) 1.14
PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res (2009) 1.12
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res (2008) 1.11
miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun (2012) 1.08
A germ cell-specific gene, Prmt5, works in somatic cell reprogramming. J Biol Chem (2011) 1.08
Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem (2013) 1.04
Methylation of histone H3 and H4 by PRMT5 regulates ribosomal RNA gene transcription. J Cell Biochem (2010) 1.01
Oxygen tension measurements of head and neck cancers. Arch Otolaryngol Head Neck Surg (1994) 0.98
Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One (2012) 0.98
Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med (1999) 0.97
The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis. Int J Mol Sci (2013) 0.97
Histone H4 acetylation differentially modulates arginine methylation by an in Cis mechanism. J Biol Chem (2011) 0.95
The exon junction complex component Y14 modulates the activity of the methylosome in biogenesis of spliceosomal small nuclear ribonucleoproteins. J Biol Chem (2011) 0.94
p53 methylation--the Arg-ument is clear. Cell Cycle (2009) 0.90
A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage. Nucleic Acids Res (2011) 0.89
Protein arginine methyltransferase 5 (PRMT5) signaling suppresses protein kinase Cδ- and p38δ-dependent signaling and keratinocyte differentiation. J Biol Chem (2011) 0.86
Fibroblast growth factor 2 (FGF-2) is a novel substrate for arginine methylation by PRMT5. Biol Chem (2009) 0.81
Methylation of eukaryotic elongation factor 2 induced by basic fibroblast growth factor via mitogen-activated protein kinase. Exp Mol Med (2011) 0.80
STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol (2008) 0.79
Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics (2011) 6.08
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A (2009) 5.72
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
A prospective study of the emergence of early behavioral signs of autism. J Am Acad Child Adolesc Psychiatry (2010) 4.10
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 3.86
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity (2005) 3.14
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol (2007) 3.09
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol Cell (2009) 2.79
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med (2004) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol (2007) 2.64
A prospective study of response to name in infants at risk for autism. Arch Pediatr Adolesc Med (2007) 2.54
miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res (2012) 2.52
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
Visual Fixation Patterns during Reciprocal Social Interaction Distinguish a Subgroup of 6-Month-Old Infants At-Risk for Autism from Comparison Infants. J Autism Dev Disord (2006) 2.40
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 2.39
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood (2004) 2.37
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol (2009) 2.34
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res (2005) 2.19
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res (2005) 2.10
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J (2007) 2.08
Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol (2006) 2.01
Human hepatic stem cell and maturational liver lineage biology. Hepatology (2011) 1.99
Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology (2006) 1.98
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood (2012) 1.97
Expression of versican 3'-untranslated region modulates endogenous microRNA functions. PLoS One (2010) 1.94
Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology (2011) 1.94
Onset patterns in autism: correspondence between home video and parent report. J Am Acad Child Adolesc Psychiatry (2011) 1.93
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood (2006) 1.92
MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS One (2009) 1.88
Beyond autism: a baby siblings research consortium study of high-risk children at three years of age. J Am Acad Child Adolesc Psychiatry (2013) 1.86
Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol (2004) 1.86
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood (2009) 1.83
Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology (2012) 1.81
Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science (2003) 1.77
Atypical object exploration at 12 months of age is associated with autism in a prospective sample. Autism (2008) 1.74
alpha(4)beta(1) Integrin activation of L-type calcium channels in vascular smooth muscle causes arteriole vasoconstriction. Circ Res (2002) 1.74
How early do parent concerns predict later autism diagnosis? J Dev Behav Pediatr (2009) 1.70
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer (2014) 1.68
The Ohio Patient Navigation Research Program: does the American Cancer Society patient navigation model improve time to resolution in patients with abnormal screening tests? Cancer Epidemiol Biomarkers Prev (2012) 1.66
The pluripotency factor LIN28 marks undifferentiated spermatogonia in mouse. BMC Dev Biol (2009) 1.66
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol (2011) 1.65
Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl (2008) 1.65
Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res (2013) 1.64
Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol (2009) 1.63
UV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b+ myeloid cell expansion. J Invest Dermatol (2011) 1.61
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res (2011) 1.61
Cholangiocarcinoma: update and future perspectives. Dig Liver Dis (2010) 1.58
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun (2009) 1.58
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma (2009) 1.58
Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol (2006) 1.57
Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol (2008) 1.57
Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry (2004) 1.56
Association of ERAP1, but not IL23R, with ankylosing spondylitis in a Han Chinese population. Arthritis Rheum (2009) 1.55
β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev (2011) 1.55
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther (2009) 1.54
Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol (2009) 1.53
Behavioral profiles of affected and unaffected siblings of children with autism: contribution of measures of mother-infant interaction and nonverbal communication. J Autism Dev Disord (2011) 1.53
IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Blood (2004) 1.52
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res (2007) 1.52
Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat (2011) 1.51
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood (2012) 1.51
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res (2013) 1.51
The biliary tree--a reservoir of multipotent stem cells. Nat Rev Gastroenterol Hepatol (2012) 1.50
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis (2011) 1.48
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother (2011) 1.47
Morphological and functional heterogeneity of the mouse intrahepatic biliary epithelium. Lab Invest (2009) 1.45
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. J Clin Oncol (2007) 1.45
Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut (2009) 1.44
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res (2005) 1.44
Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem Sci (2011) 1.44
TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol (2005) 1.39
Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment. Oncogene (2004) 1.39
Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A (2008) 1.39
The anticipated physician shortage: meeting the nation's need for physician services. Am J Med (2009) 1.38
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer (2007) 1.38
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
MicroRNA-21 regulates the self-renewal of mouse spermatogonial stem cells. Proc Natl Acad Sci U S A (2011) 1.35
Integrins as unique receptors for vascular control. J Vasc Res (2003) 1.33
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol (2005) 1.33
Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med (2009) 1.32
Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci (2002) 1.28